ClinicalTrials.gg
RecruitingNCT05696626ELAINEIIIUpdated Nov 13, 2026

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

A Phase 3 interventional study of Lasofoxifene in combination with abemaciclib and Fulvestrant in combination with abemaciclib in Metastatic Breast Cancer, sponsored by LeonaBio. Recruiting at 224 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by LeonaBio · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years later.
Updated Nov 13, 2026Site recruiting status changed1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.

Planned enrollment
6th of 55
600 · median 120
Started
2023
with 2 others
Phase 3
11 of 55
2 open now
Primary completion
2027-04
later than 15 of 33 live
Registered
39th of 55
by date

Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 6th largest by planned enrollment, is one of 3 that started in 2023, is one of 11 in phase 3, reaches primary completion later than 15 of the 33 other live ones, and was the 39th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing abemaciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation.

The main question the study aims to answer is:

  • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pre- or women or men.
  2. Locally advanced and/or ER+ breast cancer with radiological or clinical evidence of progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease.
  3. Histological or cytological confirmation of ER+/ - disease
  4. No evidence of progression for at least 6 months on an AI/CDKi combination for advanced breast cancer.
  5. At least 1 or more ESR1 point mutations in the ESR1 ligand binding domain as assessed in cell- free ctDNA obtained from a blood or breast cancer tissue.
  6. Locally advanced or metastatic breast cancer with at least 1 measurable (according to 1.1) lesion with or without non-.
  7. Subjects may have received 1 cytotoxic chemotherapy regimen in the metastatic disease setting prior to study entry, but must have recovered from chemotherapy acute toxicity excluding alopecia and Grade 2 peripheral neuropathy.
  8. (ECOG) performance score of 0 or 1
  9. Adequate organ function
  10. Able to swallow tablets
  11. are allowed only if the following 4 parameters hold:

    1. Asymptomatic,
    2. Definitively treated (e.g., radiotherapy, surgery),
    3. Not requiring up to 4 weeks before study treatment initiation, AND
    4. Central nervous system disease stable for >3 months prior to registration as documented by magnetic resonance imagining (MRI).
  12. Able to understand and voluntarily sign a written before any screening procedures.
  13. Every attempt should be made to obtain a of metastatic breast cancer tissue, when safe and feasible, to provide histological or cytological confirmation of ER+/HER2- disease as assessed by a local laboratory, according to American Society of Clinical Oncology/College of American Pathologists guidelines, using slides, paraffin blocks, or paraffin samples. If a biopsy is done, it may undergo genomic testing at some point to assess for ESR1 mutations and correlation with ctDNA results. If a biopsy is not possible or inappropriate from a clinical standpoint, the ER and HER2 status from the subject's most recent biopsy must confirm that the subject is ER+ and HER2

Exclusion criteria

Exclusion Criteria:

  1. Lymphangitic carcinomatosis involving the lung.
  2. History of Grade 3 or Grade 4 interstitial lung disease (ILD) on previous therapy.
  3. Visceral crisis in need of cytotoxic chemotherapy as assessed by the investigator.
  4. Prior progression of disease on abemaciclib, fulvestrant, or other selective estrogen receptor degrader (SERD) therapy.
  5. Subjects with a known to fulvestrant or to any of the
  6. Radiotherapy within 30 days prior to Visit 0 (Day 1) except in case of localized radiotherapy for analgesic purposes or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to Visit 0 (Day 1). Subjects must have recovered from radiotherapy toxicities prior to Visit 0 (Day 1).
  7. Known RB1 mutations or deletions that in the opinion of the investigator confer resistance to CDK4/6i. (Screening for RB1 mutation is not required for entry.)
  8. History of long (Q-T interval corrected for heart rate) syndrome or a QTc of >480 msec.
  9. History of a pulmonary embolus (PE), deep vein thrombosis (DVT), or any known thrombophilia, unless the event occurred greater than 6 months prior to screening and the subject is treated with chronic anticoagulant therapy such as apixaban (Eliquis) or rivaroxaban (Xarelto).
  10. Lasofoxifene is not recommended for use in subjects with conditions that place them at increased risk for VTEs (such as severe congestive heart failure [CHF] or prolonged immobilization).
  11. On concomitant strong inhibitors.
  12. On strong and moderate CYP3A4 inducers.
  13. Any significant co-morbidity that would impact the study or the subject's safety, including subjects with significant malabsorption.
  14. Active systemic bacterial or fungal infection (requiring intravenous [IV] antibiotics or antifungals at the time of initiating study treatment).
  15. Known infection with (HIV), virus (HBV), or virus (HCV).
  16. History of within the past 5 years (excluding breast cancer), except basal cell or squamous cell carcinoma of the skin curatively treated by surgery.
  17. Positive serum pregnancy test (only if premenopausal).
  18. Sexually active premenopausal women and men unwilling to use double-barrier .
  19. Women who are breast feeding
  20. History of non-compliance to medical regimens.
  21. Unwilling or unable to comply with the protocol.
  22. Current participation in any clinical research trial involving an drug or device within the last 30 days.
  23. Subjects with a history of familial hypertriglyceridemia or fasting triglyceride levels >880 mg/dL at screening.
  24. Fasting triglyceride level >300 mg/dL and ≤880 mg/dL at screening. Subjects may be retested and enrolled if they have a repeat fasting triglyceride level less than or equal to 300 mg/dL prior to enrollment (e.g., after adjustment with diet and/or treatment).
  25. Fasting cholesterol level >400 mg/dL at screening. Subjects may be retested and enrolled if they have a repeat fasting cholesterol level less than or equal to 400 mg/dL prior to enrollment (e.g., after adjustment with diet and/or treatment).
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Treatment

    Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.

    Drug: Lasofoxifene in combination with abemaciclib

  • Active comparator
    Reference Therapy

    Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.

    Drug: Fulvestrant in combination with abemaciclib

Interventions

  • DrugLasofoxifene in combination with abemaciclib

    Drug pages: Lasofoxifene · Abemaciclib

    5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day

  • DrugFulvestrant in combination with abemaciclib

    Drug pages: Fulvestrant · Abemaciclib

    Fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS)

    PFS is defined as the time from the date of randomization \[Visit 0 (Day 1)\] to the earliest date of first documented progression per RECIST 1.1 as determined by BICR or death due to any cause.

    Time frame: Within approximately 3 years

Secondary outcomes

  1. Objective response rate (ORR)

    ORR is defined as the percentage of subjects with measurable disease at baseline whose best overall response is either a confirmed CR or a confirmed PR according to RECIST 1.1.

    Time frame: Within approximately 3 years

  2. Overall survival (OS)

    Overall survival is defined as time from the date of Visit 0 (Day 1) to death due to any cause.

    Time frame: Within approximately 3 years

  3. Clinical benefit rate (CBR)

    CBR is defined as the percentage of subjects with best overall response of confirmed CR, confirmed PR, or stable disease (SD) with a duration of 24 weeks or longer according to RECIST 1.1. As used in this calculation, stable disease is defined as stable disease in those subjects with measurable disease plus nonPR/non progressive disease (PD) in subjects with non-measurable disease.

    Time frame: Within approximately 3 years

  4. Duration of response (DoR) in subjects with an objective response

    DoR is from the date of first documented confirmed response (CR or PR) to the date of first documented progression of disease or death due to any cause, whichever is earlier.

    Time frame: Within approximately 3 years

  5. Time to response (TTR) in subjects with an objective response

    TTR is from the date of randomization to the date of first documented confirmed response (CR or PR).

    Time frame: Within approximately 3 years

  6. Time to cytotoxic chemotherapy

    From the date of randomization to the date of first documented use of cytotoxic chemotherapy.

    Time frame: Within approximately 3 years

  7. Quality of Life (QoL) evaluated using the Functional Assessment of Cancer Therapy-Breast Cancer-Endocrine Subscale (FACT B-ES)

    Scale ranges from 'Not at all' to 'Very much'

    Time frame: Within approximately 3 years

  8. Incidence of Adverse Events (AEs) and Serious AEs

    The type, severity (graded by Common Terminology Criteria for Adverse Events \[CTCAE version 5.0\]), course, duration, seriousness, and relationship to study treatment will be assessed at each visit

    Time frame: Within approximately 3 years

07

Study locations

204 of 224 sites recruiting

Showing the first 100 of 224 sites across 17 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Goetz MP, Wander SA, Bachelot T, de Nonneville A, Gal-Yam EN, Sammons SL, Shen S, Twelves C, Boruta G, Portman DJ, Damodaran S. ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1-mutated, metastatic breast cancer. Future Oncol. 2025 May;21(11):1317-1324. doi: 10.1080/14796694.2025.2481825. Epub 2025 Apr 13. PubMed 40222048 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Apr 2027, 42 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 42 months is close to that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2023
First posted
Jan 25, 2023
StartActual
Oct 31, 2023
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed. 20 sites changed recruiting status (14 now recruiting, 4 now withdrawn, …)
Show 20 sites
  • Allina Health System DBA Virginia Piper Cancer Institute · Minneapolis, United StatesRecruiting→Completed
  • University Hospitals Seidman Cancer Center · Cleveland, United StatesNot yet recruiting→Recruiting
  • Cliniques Universitaires Saint-Luc · Brussels, BelgiumNot yet recruiting→Recruiting
  • Institut Gustave Roussy · Villejuif, FranceNot yet recruiting→Recruiting
  • Azienda Ospedaliero Universitaria Maggiore Della Carita · Novara, ItalyNot yet recruiting→Withdrawn
  • Istituto Oncologico Veneto-I.R.C.C.S. - Ospedale Busonera · Padova, ItalyNot yet recruiting→Recruiting
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, I Klinika Radioterapii i Chemioterapii · Gliwice, PolandNot yet recruiting→Withdrawn
  • Memorial Healthcare International SRL · Bucharest, RomaniaNot yet recruiting→Recruiting
  • Asan Medical Center · Seoul, South KoreaNot yet recruiting→Withdrawn
  • Severance Hospital, Yonsei University Health System · Seoul, South KoreaNot yet recruiting→Withdrawn
  • Istanbul University CAPA Medical Faculty · Çapa, Turkey (Türkiye)Not yet recruiting→Recruiting
  • Suat Seren Training and Research Hospital · Konak, Turkey (Türkiye)Not yet recruiting→Recruiting
  • Kocaeli University Research and Application Hospital · İzmit, Turkey (Türkiye)Not yet recruiting→Recruiting
  • Ankara University Medical Faculty Medical Oncology Department · Ankara, Turkey (Türkiye)Not yet recruiting→Recruiting
  • Uludag University Faculty of Medicine Hospital · Bursa, Turkey (Türkiye)Not yet recruiting→Recruiting
  • Trakya University Medical Faculty Hospital · Edirne, Turkey (Türkiye)Not yet recruiting→Recruiting
  • Medical Point Izmir Hospital · Izmir, Turkey (Türkiye)Not yet recruiting→Recruiting
  • Velindre Cancer Center · Cardiff, United KingdomNot yet recruiting→Recruiting
  • Beth Israel Deaconess Medical Center · Boston, United StatesRecruiting→Completed
  • Ege University Medical Faculty Hospital · Bornova, Turkey (Türkiye)Not yet recruiting→Recruiting
Show site
  • Sheba Medical Center · Tel HaShomer, Israel
Show 1 removed
  • Sheba Medical Center · Tel Litwinsky, Israel
across 2 updates, Oct 29, 2026 – Nov 13, 2026
Site contacts
Changed at 13 sites. See the sites
Show 13 sites
  • University of Arizona - Cancer Center · Tucson, United StatesContact c•••@arizona.edu→u•••@arizona.edu
  • Allina Health System DBA Virginia Piper Cancer Institute · Minneapolis, United StatesContact removed d•••@allina.com
  • Duke University Medical Center · Durham, United StatesContact none listed→•••1278
  • The Affiliated Hospital of Qingdao University · Qingdao, ChinaContact h•••@126.com · •••5787→h•••@126.com · •••5787
  • Kaplan Medical Center · Rehovot, IsraelContact a•••@clalit.org.il→a•••@clalit.org.il · •••0814
  • Azienda Ospedaliero Universitaria Maggiore Della Carita · Novara, ItalyContact removed a•••@uniupo.it
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, I Klinika Radioterapii i Chemioterapii · Gliwice, PolandContact removed m•••@io.gliwice.pl · •••8721
  • Mazowiecki Szpital Onkologiczny · Wieliszew, PolandContact r•••@szpitalonkologiczny.pl · •••1500→s•••@szpitalonkologiczny.pl · •••1500
  • Asan Medical Center · Seoul, South KoreaContact removed s•••@amc.seoul.kr · •••3217
  • Severance Hospital, Yonsei University Health System · Seoul, South KoreaContact removed o•••@yuhs.ac · •••8135
  • Velindre Cancer Center · Cardiff, United KingdomContact none listed→s•••@wales.nhs.uk
  • Nottingham City Hospital · Nottingham, United KingdomContact s•••@nhs.uk→s•••@nhs.net
  • Beth Israel Deaconess Medical Center · Boston, United StatesContact removed s•••@bidmc.harvard.edu
across 2 updates, Oct 29, 2026 – Nov 13, 2026
Show all 2 updates
  1. Nov 13, 2026
    2 sites changed recruiting status (1 now completed, 1 now recruiting)
    Show 2 sites
    • Beth Israel Deaconess Medical Center · Boston, United StatesRecruiting→Completed
    • Ege University Medical Faculty Hospital · Bornova, Turkey (Türkiye)Not yet recruiting→Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Beth Israel Deaconess Medical Center · Boston, United StatesContact removed s•••@bidmc.harvard.edu
  2. Oct 29, 2026
    1 site added, 1 site removed. 18 sites changed recruiting status (13 now recruiting, 4 now withdrawn, …)
    Show 18 sites
    • Allina Health System DBA Virginia Piper Cancer Institute · Minneapolis, United StatesRecruiting→Completed
    • University Hospitals Seidman Cancer Center · Cleveland, United StatesNot yet recruiting→Recruiting
    • Cliniques Universitaires Saint-Luc · Brussels, BelgiumNot yet recruiting→Recruiting
    • Institut Gustave Roussy · Villejuif, FranceNot yet recruiting→Recruiting
    • Azienda Ospedaliero Universitaria Maggiore Della Carita · Novara, ItalyNot yet recruiting→Withdrawn
    • Istituto Oncologico Veneto-I.R.C.C.S. - Ospedale Busonera · Padova, ItalyNot yet recruiting→Recruiting
    • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, I Klinika Radioterapii i Chemioterapii · Gliwice, PolandNot yet recruiting→Withdrawn
    • Memorial Healthcare International SRL · Bucharest, RomaniaNot yet recruiting→Recruiting
    • Asan Medical Center · Seoul, South KoreaNot yet recruiting→Withdrawn
    • Severance Hospital, Yonsei University Health System · Seoul, South KoreaNot yet recruiting→Withdrawn
    • Istanbul University CAPA Medical Faculty · Çapa, Turkey (Türkiye)Not yet recruiting→Recruiting
    • Suat Seren Training and Research Hospital · Konak, Turkey (Türkiye)Not yet recruiting→Recruiting
    • Kocaeli University Research and Application Hospital · İzmit, Turkey (Türkiye)Not yet recruiting→Recruiting
    • Ankara University Medical Faculty Medical Oncology Department · Ankara, Turkey (Türkiye)Not yet recruiting→Recruiting
    • Uludag University Faculty of Medicine Hospital · Bursa, Turkey (Türkiye)Not yet recruiting→Recruiting
    • Trakya University Medical Faculty Hospital · Edirne, Turkey (Türkiye)Not yet recruiting→Recruiting
    • Medical Point Izmir Hospital · Izmir, Turkey (Türkiye)Not yet recruiting→Recruiting
    • Velindre Cancer Center · Cardiff, United KingdomNot yet recruiting→Recruiting
    Show site
    • Sheba Medical Center · Tel HaShomer, Israel
    Show 1 removed
    • Sheba Medical Center · Tel Litwinsky, Israel
    Site contacts Changed at 12 sites. See the sites
    Show 12 sites
    • University of Arizona - Cancer Center · Tucson, United StatesContact c•••@arizona.edu→u•••@arizona.edu
    • Allina Health System DBA Virginia Piper Cancer Institute · Minneapolis, United StatesContact removed d•••@allina.com
    • Duke University Medical Center · Durham, United StatesContact none listed→•••1278
    • The Affiliated Hospital of Qingdao University · Qingdao, ChinaContact h•••@126.com · •••5787→h•••@126.com · •••5787
    • Kaplan Medical Center · Rehovot, IsraelContact a•••@clalit.org.il→a•••@clalit.org.il · •••0814
    • Azienda Ospedaliero Universitaria Maggiore Della Carita · Novara, ItalyContact removed a•••@uniupo.it
    • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, I Klinika Radioterapii i Chemioterapii · Gliwice, PolandContact removed m•••@io.gliwice.pl · •••8721
    • Mazowiecki Szpital Onkologiczny · Wieliszew, PolandContact r•••@szpitalonkologiczny.pl · •••1500→s•••@szpitalonkologiczny.pl · •••1500
    • Asan Medical Center · Seoul, South KoreaContact removed s•••@amc.seoul.kr · •••3217
    • Severance Hospital, Yonsei University Health System · Seoul, South KoreaContact removed o•••@yuhs.ac · •••8135
    • Velindre Cancer Center · Cardiff, United KingdomContact none listed→s•••@wales.nhs.uk
    • Nottingham City Hospital · Nottingham, United KingdomContact s•••@nhs.uk→s•••@nhs.net
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05696626
Lead sponsor
LeonaBio
Responsible party
Sponsor
First posted
Jan 25, 2023
Start date
Oct 31, 2023
Primary completion
Apr 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Simon Daggett - Senior Vice President, Clinical Operations
Contact
clinicaltrials@leonabio.com
(909) 374-3793 ext. (425) 620-8772

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lasofoxifene · Abemaciclib

Start the discussion